Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors
Articolo
Data di Pubblicazione:
2015
Citazione:
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors / Matino, Davide; Makris, Michael; Dwan, Kerry; D'Amico, Roberto; Iorio, Alfonso. - In: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. - ISSN 1469-493X. - ELETTRONICO. - 2015:12(2015), pp. 1-24. [10.1002/14651858.CD004449.pub4]
Abstract:
In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies, known as 'inhibitors'. Drugs insensitive to such antibodies, either recombinant or plasma-derived, are called factor VIII 'by-passing' agents and used for treatment of bleeding in people with inhibitors.
Tipologia CRIS:
Articolo su rivista
Keywords:
Acute Disease; Blood Coagulation Factors [therapeutic use]; Factor VIII [immunology; therapeutic use]; Factor VIIa [therapeutic use]; Hemophilia A [blood; drug therapy]; Hemophilia B [blood; drug therapy]; Hemorrhage [drug therapy]; Randomized Controlled Trials as Topic; Recombinant Proteins [therapeutic use]
Elenco autori:
Matino, Davide; Makris, Michael; Dwan, Kerry; D'Amico, Roberto; Iorio, Alfonso
Link alla scheda completa:
Pubblicato in: